Categories
Change Password!
Reset Password!
Bone target therapies significantly improve the overall
survival rates, and prevent recurrence of breast cancer cells and thus, its use
should be encouraged in the treatment of advanced breast cancer.
Breast cancer is one of the most frequently occurring cancers in women. Women with breast cancer also suffer from bone destruction problems like fractures and osteoporosis. Cancer treatment or surgery brings about significant changes in the body, finally resulting in bone loss.
Bone targeted therapies are not merely crucial for bone
health, but also helps in preventing cancer recurrence and improves overall
prognosis. In general, 70% of women with breast cancer take bisphosphonates or
denosumab to avert treatment-related osteoporosis and skeletal-related events
(SREs). Among bisphosphonates, zoledronic acid exhibits great treatment
importance. Recent evidence has suggested the superiority of intravenous
bisphosphonate administration over oral administration. The trials outcomes
also suggested the superior safety profile of denosumab over zoledronic
acid.
As per the latest research data, a significant
improvement in overall survival and prevention of cancer cells at all the significant
sites has been noted with bone-targeted therapies. The enhanced bone turnover
is both an aftereffect and a driving factor for the formation of bone lesions,
tumor expansion and activation of disseminated tumor cells, leading to bone
relapses.
The investigators have collected the latest evidence on
the efficacy of bone-targeted therapies in treating advanced breast cancer. The
primary focus is to study the effect of bone target therapies on bone health
and anti-cancer activity. Current guideline recommendations, the pathogenesis
of bone metastasis, mechanism of action and side effects related to the use of
bone-targeted therapies have been detailed. Thorough research about
bisphosphonates use and denosumab in initial stages of breast cancer during
adjuvant treatment with aromatase inhibitors has also been carried out.
Swiss Med Wkly. 2017 Jul 11;100:w14440
Bone targeted therapies in advanced breast cancer
Biskup E et al.
Comments (0)